» Articles » PMID: 24526094

Percutaneous Renal Biopsy of Native Kidneys: a Single-center Experience of 1,055 Biopsies

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 2014 Feb 15
PMID 24526094
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Percutaneous renal biopsy (PRB) of native kidneys is an essential tool in the diagnosis and management of renal disease. We report one of the largest single-center experiences on the success and safety of the procedure.

Methods: From June 1983 to March 2012, 1,055 adults underwent PRB using real-time ultrasound guidance and 14-gauge biopsy needles. Data were collected prospectively for 826 biopsies (78%). Statistical analysis was performed using the Mann-Whitney test, Wilcoxon matched pairs test and Kruskal-Wallis test for continuous data or the Fisher's exact test and χ(2) test for categorical data. Multivariate analysis using logistic regression was performed to determine which feature at baseline was predictive of a complication following renal biopsy.

Results: Patients were aged 46 ± 17 years; 38% were male, 40% were white and 43% were African-American. Serum creatinine (SCr) was 2.3 ± 2.3 mg/dl (>1.5 mg/dl in 47%). The pre-PRB hemoglobin was 12 ± 2 g/dl (<11.0 g/dl in 35%). Adequate tissue for diagnosis was obtained in 99% of biopsies. Minor complications occurred in 8.1% of biopsies (mainly gross hematuria, in 4.5%). Major complications occurred in 6.6% of biopsies, with transfusions required in 5.3%. Only 1 death (0.09%) resulted from post-PRB bleeding. By multivariate analysis, baseline features predictive of a complication were systolic blood pressure >170 mm Hg (OR 4.2, 95% CI 1.8-9.8), bleeding time >7.5 min (OR 1.7, CI 1.2-2.5) and SCr >3.5 mg/dl (OR 1.8, CI 1.2-2.9).

Conclusions: PRB of native kidneys using real-time ultrasound with a 14-gauge automated needle remains a successful and safe procedure.

Citing Articles

Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician.

Java A, Fuller L Kidney Med. 2025; 7(1):100928.

PMID: 39758154 PMC: 11699595. DOI: 10.1016/j.xkme.2024.100928.


To biopsy or not to biopsy a teenager with idiopathic nephrotic syndrome? Biopsy first.

Bigatti C, Chiarenza D, Angeletti A Pediatr Nephrol. 2024; 40(2):571-578.

PMID: 39251432 PMC: 11666677. DOI: 10.1007/s00467-024-06510-6.


Ultrasound-guided kidney biopsy: a ten-year retrospective single-center experience and the promising role of clinical hypnosis.

Angioi A, Mascia G, Sirigu D, Cao R, Bianco P, Onnis D Int Urol Nephrol. 2024; 57(2):553-559.

PMID: 39237701 PMC: 11772539. DOI: 10.1007/s11255-024-04196-1.


Successful Endovascular Treatment of Postbiopsy AVF in Transplanted Kidneys: Lessons Learned from Two Cases in Multiorgan Transplant Recipients.

Zelalic S, Simunov B, Maksimovic B, Muzar R, Laganovic M, Vidjak V Int J Angiol. 2024; 33(3):198-201.

PMID: 39131812 PMC: 11315601. DOI: 10.1055/s-0043-1777256.


Automatic renal carcinoma biopsy guidance using forward-viewing endoscopic optical coherence tomography and deep learning.

Wang C, Cui H, Zhang Q, Calle P, Yan Y, Yan F Commun Eng. 2024; 3(1):107.

PMID: 39095532 PMC: 11297278. DOI: 10.1038/s44172-024-00254-9.